diabetes is associated with high mortality rate, emphasizing the necessity to improve
glycemic control. Angiotensin-converting enzyme 2 (ACE2) is the receptor responsible for
SARS-CoV-2 access to human cells, and ACE2 expression is increased in patients with
diabetes and hypertension treated with ACE-inhibitors or angiotensin II receptor blockers.
We hypothesize that an upregulation of ACE2 due to its non-enzymatic glycation could be …